Frost & Sullivan and Medtide Inc. Release White Paper on the Global Peptide and Oligonucleotide Drug Industry

Growing use of GLP-1 therapies and advances in oligonucleotide delivery are changing what drugmakers need from their manufacturing partners.

Shanghai, China - 20 Nov., 2026 - Frost & Sullivan and Medtide Inc. have jointly released the 2026 Global Peptide and Oligonucleotide Drug Industry White Paper. The report examines the global market for peptide and oligonucleotide therapeutics, collectively known as TIDES, and the manufacturing capabilities needed to bring these medicines from clinical development to commercial supply.

Recommended for you